WHAT'S UP $DOC? Guidance Raised, Fundamentals Improving! $DOC delivered a solid Q3 2026, with encouraging signs across healthcare real estate. 📈 Key takeaways: ✅ FY26 FFO guidance raised to $1.77/share midpoint ✅ Same-store NOI growth outlook raised 50 bps ✅ Senior housing NOI guidance raised 250 bps ✅ Life science NOI guidance raised 100 bps ✅ Outpatient medical NOI guidance raised 25 bps ✅ Lab occupancy +20 bps sequentially ✅ Outpatient occupancy +10 bps sequentially ✅ Net debt/EBITDA remains healthy at 4.7x 💰 $DOC also acquired 4 life science properties for $233M, with potential stabilized yields of 9–10%. 🎯 Analyst price target: $23, implying approximately 18% upside from $19.50. My takeaway: Improving occupancy, stronger operating fundamentals, and senior housing momentum are encouraging. However, lab leasing risk and higher refinancing costs remain important considerations. The healthcare REIT recovery may be gaining traction! Long $DOC
View original →
